Key Drivers
- Exceptional gross margins
- Very strong liquidity
- High R&D burden
AIAI Summary
LGND's decisive shift into a capital‑efficient royalty aggregator meaningfully reduces binary biotech risk and makes near‑term value hinge on repeatable, accretive royalty origination and disciplined capital deployment rather than clinical outcomes. Key action: monitor quarterly royalty growth cadence, evidence of diversified deal closings (vs. partner concentration), and use of the ~$1bn deployable capital—failure to source accretive royalties or a break below the mid‑high $180s support would materially compress the premium multiple.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Exceptional gross margins
- •Very strong liquidity
- •High R&D burden
LGND combines exceptionally high gross margins and strong cash generation with very strong liquidity and moderate leverage, but faces heavy R&D/investment intensity and rich valuation that heighten execution risk.
Price Behavior
Key Price Behavior Insights:
- •Above last-month SMA
- •Short-term weakness
- •Elevated volatility
LGND is marginally above its last-month SMA (intermediate trend intact) but undercutting the short-term average after the 2026-03-11 peak, facing resistance near the early‑March high (~$220+) with support around $185–$190 and elevated volatility.
Price swung from mid-$180s to >$220 last month, indicating elevated short-term volatility
Sentiment & News
Key News Insights:
- •48% royalty growth
- •BofA Buy
- •Insider/institutional selling
Ligand has renewed analyst interest (BofA Buy) after strong FY2025 results—48% royalty growth and reiterated 2026 guidance—paired with active investor outreach but tempered by insider and institutional selling.
Strong royalty-driven results and fresh analyst coverage should support near-term valuation upside, although insider and fund-level sales warrant cautious monitoring
Similar Companies in Healthcare
Other companies in the same sector with AI ratings